In the rare disease area, the NanoBriva™ platform allows for the design and production of recombinant therapeutic proteins such as lysosomal enzymes developed within internal R&D programs.
Samabriva is developing its own therapeutic products and is keen to establish partnerships to develop new first-in-class products in the rare diseases area as part of a collaboration.
If you are interested
CONTACT US
